TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03900949
Drug: Midostaurin
Normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03353233
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
Study: NCT00464880
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03964558
Drug: [14C]-acebilustat solution
DrugBank: Acebilustat (DB15385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
Study: NCT00795678
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
Study: NCT00795678
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: : Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
Study: NCT00795678
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
Study: NCT00795678
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
Study: NCT00795678
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
Study: NCT05705089
Drug: Rivaroxaban 15 MG
Normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
Study: NCT05705089
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
Study: NCT01806662
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection of monoclonal antibody against the p40 subunit of IL-12/23
Study: NCT00196846
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01947855
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin low dose
Study: NCT01947855
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin high dose tablet once daily
Study: NCT03225313
Drug: Bupivacaine Hydrochloride 0.5% Injection Solution_#4
Normalized name: Bupivacaine Hydrochloride 0.5% Injection Solution_#4
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultra sound guided injection into the rectus sheath
Study: NCT03225313
Drug: Bupivacaine Hydrochloride 0.5% Injection Solution_#4
Normalized name: Bupivacaine Hydrochloride 0.5% Injection Solution_#4
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: locally surrounding the hernia
Study: NCT00883129
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
Study: NCT00608075
Drug: lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg - 1800 mg per day
Study: NCT00608075
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 - 1800 mg
Study: NCT01701180
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 IU; 3 puffs per nostril, each with 4 IU OXT
Study: NCT00407966
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00407966
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00407966
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02831478
Drug: Sunscreen Lotion (RB# T78-190B)
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied liberally to the skin
Study: NCT01898884
Drug: VP 20629
Normalized name: etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02361801
Drug: Liberal dobutamine protocol
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive dobutamine at the cardiopulmonary bypass weaning.
Study: NCT02361801
Drug: Restrictive dobutamine protocol
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output \< 2 mL/Kg/h despite adequate fluid replacement.
Study: NCT01658215
Drug: V0116 transdermal patch (Test treatment )
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01658215
Drug: Nicotine transdermal patch (Reference treatment )
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04583592
Drug: Camostat Mesilate
Normalized name: Camostat mesilate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
Study: NCT03036488
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
Study: NCT03036488
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
Study: NCT03036488
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
Study: NCT04491773
Drug: Tadalafil 20 MG
Normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
Study: NCT01482442
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
Study: NCT01482442
Drug: SIR-Sphere
Normalized name: Coccidioides immitis spherule Injectable Solution [Spherusol]
DrugBank: Coccidioides immitis spherule (DB11294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
Study: NCT03198819
Drug: Local Rifampisin and İnrtravenous cefotaxime
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02230228
Drug: ALK-001 (No generic name)
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily, oral administration of ALK-001 capsules.
Study: NCT00013702
Drug: Adefovir
Normalized name: Adefovir
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03894007
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.
Study: NCT03894007
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 6 iv, day 1 every third week, 4 courses preoperatively.
Study: NCT03894007
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.
Study: NCT03894007
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.
Study: NCT03894007
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively
Study: NCT03894007
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.
Study: NCT03894007
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.
Study: NCT03894007
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.
Study: NCT02255435
Drug: Omaveloxolone Capsules, 2.5 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255435
Drug: Omaveloxolone Capsules, 5 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255435
Drug: Omaveloxolone Capsules, 10 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255435
Drug: Omaveloxolone Capsules, 20 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255435
Drug: Omaveloxolone Capsules, 40 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255435
Drug: Omaveloxolone Capsules, 80 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255435
Drug: Omaveloxolone Capsules, 160 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255435
Drug: Omaveloxolone Capsules, 300 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03414814
Drug: Osimertinib 80 MG [Tagrisso]
Normalized name: osimertinib 80 MG [Tagrisso]
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib 80mg once daily until disease progression
Study: NCT03161379
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
Study: NCT03161379
Drug: GVAX Pancreas Vaccine
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
Study: NCT03534947
Drug: Sonidegib
Normalized name: Sonidegib
DrugBank: Sonidegib (DB09143)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.
Study: NCT03534947
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.
Study: NCT02255435
Drug: Omaveloxolone Capsules, 150 mg
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00129844
Drug: Motexafin Gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02787746
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients were treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the dose could be reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who could not endure the 10mg/d titration the 2nd time and were put back to 5mg/d or discontinuance of Aricept® should be considered as withdrawal from the study. There were a visit (visit 1) at week 0, the end of week 4 (visit 2) and the end of week 20 (visit 3), respectively.
Study: NCT01754402
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
Study: NCT01754402
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
Study: NCT01754402
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
Study: NCT01075308
Drug: HDAC inhibitor SB939
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
Study: NCT03254459
Drug: Buprenorphine Sublingual Spray
Normalized name: buprenorphine Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5 mg Sublingual Spray
Study: NCT03254459
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg Intravenous Injection
Study: NCT03254459
Drug: Oxycodone Hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg tablet
Study: NCT03254459
Drug: Zofran
Normalized name: Zofran
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
Study: NCT01811056
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone use outside of the center
Study: NCT04249232
Drug: Abaloparatide 80 micrograms per Pen dose
Normalized name: abaloparatide
DrugBank: Abaloparatide (DB05084)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: prefilled injector pen to deliver 80 micrograms daily subcutaneously
Study: NCT03830905
Drug: XC221
Normalized name: XC221
DrugBank: XC221 (DB16503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 200 mg XC221 once a day during 3 days
Study: NCT00717704
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: by vein once every 3 weeks
Study: NCT00717704
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: by mouth once daily
Study: NCT03607513
Drug: JNJ-64264681
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.
Study: NCT01588418
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
Study: NCT01643031
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
Study: NCT01643031
Drug: Continued clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
Study: NCT02384915
Drug: prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02384915
Drug: mepivacaine
Normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01042691
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
Study: NCT01012219
Drug: niacin (+) laropiprant
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
Study: NCT01012219
Drug: Comparator: clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75 mg oral tablet once daily for 7 days
Study: NCT01012219
Drug: Comparator: laropiprant
DrugBank: Laropiprant (DB11629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral tablet once daily for 7 days
Study: NCT00674596
Drug: ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ramipril 10 mg/day during 3 months
Study: NCT02432560
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
Study: NCT01710137
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02432560
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
Study: NCT03464292
Drug: Capsaicin Patch 8% or 0.1% Capsaicin Cream
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream
Study: NCT01734889
Drug: Nitisinone
Normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral suspension